Brand name : NAMENDA
US FDA Approval :October 2003
NMDA (N-methyl-D-aspartate) receptor antagonist
Indicated for the treatment of moderate to severe Alzheimer’s Disease
Effectiveness of Nutrition Information Provision on Food Consumption Behavior among Undergraduate Students in Urban Areas
โดย
นพพล วิทย์วรพงศ์
สันต์ สัมปัตตะวนิช
ธนะพงษ์ โพธิปิติ
ธานี ชัยวัฒน์
พัชรสุทธิ์ สุจริตตานนท์
ธีระ วรธนารัตน์
VILDAGLIPTIN: DPP-IV INHIBITOR
Generic name: Vildagliptin
Brand name: Galvus
Treatment for: type 2 diabetes
selective inhibitor of dipeptidyl-
peptidase IV (DPP-IV)
- the first in a new class of oral antidiabetic agents
- known as dipeptidyl peptidase IV inhibitors
(DPP-IV) inhibitors
Tarceva® ( erlotinib )
Indicated for :the treatment of locally advanced or metastatic non-small cell lung cancer that has failed prior chemotherapy
Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor
7. TabletDisintegration
Free drug
(active)
Drug-Protein complex
(inactive)
Blood vessel
DISTRIBUTIONDISTRIBUTION
Other sitesOther sites
Target site of actionTarget site of action
(Adequate concentration)
Adverse effects
Drug action
Dissolution
ABSORPTIONABSORPTION
BIOTRANSFORMATIONBIOTRANSFORMATION
EXCRETIONEXCRETION
Metabolites
Pharmcokinetic